Full text not available from this repository.

Abstract

The Multicenter Selective Lymphadenectomy Trials indicate that there are no overall or melanoma-specificsurvival advantages to performing sentinel lymph node biopsy (SLNB) followed by immediate completionlymph node dissection compared with wide excision and observation for patients with positive sentinelnodes. These results make SLNB solely a staging procedure. The role of SLNB in the management ofpatients with melanoma deserves reappraisal. The potential marginal benefit of SLNB beyond the clinicaland pathologic features of the melanoma has not been well studied. The use of sentinel lymph node statusalone to accept and stratify patients into trials or to receive adjuvant treatment is not rational.

Item Type:	Article
Authors/Creators:	Bigby, M and Zagarella, S and Sladden, M and Popescu, CM
Keywords:	Breslow thickness, hazard ration, immediate completion lymph node dissection, melanoma multicenter selective lymphadenectomy trial, prognosis, sentinel lymph node biopsy, survival
Journal or Publication Title:	Journal of the American Academy of Dermatology
Publisher:	Mosby
ISSN:	0190-9622
DOI / ID Number:	10.1016/j.jaad.2018.11.026
Copyright Information:	Copyright 2018 American Academy of Dermatology, Inc.
Item Statistics:	View statistics for this item

Actions (login required)

Item Control Page